학술논문
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Document Type
Article
Author
Schoenfeld, Jonathan D ; Giobbie-Hurder, Anita; Ranasinghe, Srinika; Kao, Katrina Z; Lako, Ana; Tsuji, Junko; Liu, Yang; Brennick, Ryan C; Gentzler, Ryan D; Lee, Carrie; Hubbard, Joleen; Arnold, Susanne M; Abbruzzese, James L; Jabbour, Salma K; Uboha, Nataliya V; Stephans, Kevin L; Johnson, Jennifer M; Park, Haeseong; Villaruz, Liza C; Sharon, Elad; Streicher, Howard; Ahmed, Mansoor M; Lyon, Hayley; Cibuskis, Carrie; Lennon, Niall; Jhaveri, Aashna; Yang, Lin; Altreuter, Jennifer; Gunasti, Lauren; Weirather, Jason L; Mak, Raymond H; Awad, Mark M; Rodig, Scott J; Chen, Helen X; Wu, Catherine J; Monjazeb, Arta M; Hodi, F Stephen
Source
In The Lancet Oncology February 2022 23(2):279-291
Subject
Language
ISSN
1470-2045